Journal of Applied Physiology, Vol 80, Issue 1 140-148, Copyright © 1996 by American Physiological Society

ARTICLES

Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects

J. A. Widness, P. Veng-Pedersen, C. Peters, L. M. Pereira, R. L. Schmidt and L. S. Lowe
Department of Pediatrics, College of Medicine, University of Iowa, Iowa City 52242, USA.

Erythropoietin (EPO) pharmacokinetic studies were performed in premature infants (birth weight < 1.25 kg) and normal adults. Infants were divided into two subgroups on the basis of whether they received chronic treatment with recombinant human EPO (rhEPO; 500 IU.kg-1.wk-1 for 6 wk) beginning at 2-4 wk of life. Ten adults and seven rhEPO-treated infants underwent intravenous pharmacokinetic studies at escalating rhEPO doses: 10, 100, and 500 IU/kg. To test for pharmacokinetic developmental and treatment effects, an equal number of non-EPO- and EPO-treated infants were studied with 100 IU/kg on the last day of treatment. Compared with adults, very low birth weight infants demonstrated significantly greater plasma clearance and distribution volume and significantly shorter fractional elimination times (FET) and mean residence time (MRT) at all three rhEPO doses. Both infants and adults demonstrated nonlinear EPO elimination, i.e., increasing rhEPO dosing was associated with decreasing plasma clearance and increasing FET and MRT. In the absence of rhEPO treatment there were no pharmacokinetic differences between the two subgroups of infants studied 6 wk apart. In contrast, the rhEPO-treated infant subgroup demonstrated a significant increase in clearance and a decrease in FET and MRT following 6 wk of treatment. Enhancement of rhEPO efficacy in the prevention and treatment of anemia in premature infants may require higher doses administered in a progressively increasing fashion.

This article has been cited by other articles:

				S. E. Juul, R. J. McPherson, L. A. Bauer, K. J. Ledbetter, C. A. Gleason, and D. E. Mayock A Phase I/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety Pediatrics, August 1, 2008; 122(2): 383 - 391. [Abstract] [Full Text] [PDF]

				R. D. Semba and S. E. Juul Erythropoietin in Human Milk: Physiology and Role in Infant Health J Hum Lact, August 1, 2002; 18(3): 252 - 261. [Abstract] [PDF]

				S. Chapel, P. Veng-Pedersen, R. J. Hohl, R. L. Schmidt, E. M. McGuire, and J. A. Widness Changes in Erythropoietin Pharmacokinetics following Busulfan-Induced Bone Marrow Ablation in Sheep: Evidence for Bone Marrow as a Major Erythropoietin Elimination Pathway J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 820 - 824. [Abstract] [Full Text] [PDF]

				M. S. Brown and J. F. Keith III Comparison Between Two and Five Doses a Week of Recombinant Human Erythropoietin for Anemia of Prematurity: A Randomized Trial Pediatrics, August 1, 1999; 104(2): 210 - 215. [Abstract] [Full Text]

				K. M. Moritz, G. B. Lim, and E. M. Wintour Developmental regulation of erythropoietin and erythropoiesis Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1997; 273(6): R1829 - R1844. [Abstract] [Full Text] [PDF]